These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 446515)

  • 1. Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man. I. Metabolites of DBD.
    Horváth IP; Csetényi J; Kerpel-Fronius S; Hindy I; Eckhardt S
    Eur J Cancer (1965); 1979 Mar; 15(3):337-44. PubMed ID: 446515
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man--II. pharmacokinetics of DBD.
    Horváth IP; Csetényi J; Hindy I; Kerpel-Fronius S; Institoris I; Hegedüs I; Eckhardt S
    Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1211-9. PubMed ID: 6891658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of dianhydrogalactitol DAG in patients: a comparison with the human disposition of dibromodulcitol DBD.
    Horváth IP; Csetényi J; Kerpel-Fronius S; Hegedüs L; Kanyár B; Eckhardt S
    Eur J Cancer Clin Oncol; 1986 Feb; 22(2):163-71. PubMed ID: 3699079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of dibromodulcitol in humans: a phase I study.
    Kelley SL; Peters WP; Andersen J; Furlong EA; Frei E; Henner WD
    J Clin Oncol; 1986 May; 4(5):753-61. PubMed ID: 3517245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The distribution of [3H]-dibromodulcitol in the central nervous system of patients with brain tumour.
    Csetényi J; Afra D; Kerpel-Fronius S; Horváth IP; Institoris L; Eckhardt S
    Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1389-92. PubMed ID: 6685628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The distribution of bromine content of dibromodulcitol in the central nervous system of patients with malignant gliomas.
    Sziklai IL; Afra D; Ordogh M; Institoris L; Kerpel-Fronius S; Szabo E
    Eur J Cancer; 1990 Feb; 26(2):79-82. PubMed ID: 2157475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rat liver-mediated degradation of dibromodulcitol.
    Csetényi J; Gáti E; Hegedüs L; Horváth IP; Holczinger L
    Eur J Cancer Clin Oncol; 1985 Jul; 21(7):881-5. PubMed ID: 4043174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observations on dibromodulcitol (DBD)-mitolactol-treatment.
    Perényl G; Büttner K; Dénes L
    Ther Hung; 1977; 25(1):16-9. PubMed ID: 854865
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials with the hexitol derivatives in the U.S.
    Chiuten DF; Rozencweig M; Von Hoff DD; Muggia FM
    Cancer; 1981 Feb; 47(3):442-51. PubMed ID: 6784907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
    Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma.
    Tormey DC; Simon R; Falkson G; Bull J; Band P; Perlin E; Blom J
    Cancer Res; 1977 Feb; 37(2):529-34. PubMed ID: 832277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of 3H-dibromodulcitol and 3H-dianhydrodulcitol into ascites tumor cells. Autoradiographic study.
    Kopper L; Lapis K; Institóris L
    Neoplasma; 1976; 23(1):47-52. PubMed ID: 1272473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies on Elobromol in children with brain tumors.
    Paál C; Erdélyi-Tóth V; Pap E; Csáki C; Ferencz T; Schuler D; Borsi JD
    Anticancer Drugs; 1994 Oct; 5(5):539-47. PubMed ID: 7858286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot studies of various combinations of dibromodulcitol, VP-16, and AMSA.
    Eagan RT
    Oncology; 1982; 39(5):295-7. PubMed ID: 6896559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sister chromatid exchanges in lymphocyte cultures of patients previously treated with dibromodulcitol.
    Ansell SM; Jansen van Rensburg CE; Rapoport BL; Gresse P; Cloete EV; van Staden AM; Stevens K; Falkson CI; Falkson G
    Oncology; 1991; 48(3):253-7. PubMed ID: 2023706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer.
    Falkson G; Gelman RS; Dreicer R; Tormey DC; Alberts AS; Coccia-Portugal MA; Rushing D; Bennett JM
    J Clin Oncol; 1989 Sep; 7(9):1252-9. PubMed ID: 2671284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenicity of dibromodulcitol (DBD), an alkylating anticancer drug) and its mono- and bifunctional conversion products studied by the Salmonella/microsome assay.
    Tóth K; Sugár J; Somfai-Relle S; Hedegüs L
    Carcinogenesis; 1982; 3(3):333-6. PubMed ID: 7044598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic study of dibromodulcitol in children with brain tumors].
    Paál K; Erdélyi-Tóth V; Pap E; Csáki C; Ferencz T; Schuler D; Borsi J
    Orv Hetil; 1994 Nov; 135(46):2527-34. PubMed ID: 7800388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of BCNU-induced cytotoxicity and sister chromatid exchanges by dibromodulcitol in vitro.
    Pulst SM; Deen DF
    Anticancer Res; 1990; 10(6):1647-50. PubMed ID: 2285238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of cervix cancer with mitolactol (dibromodulcitol, NSC 104800) and cisplatin. A phase I study of the Gynecologic Oncology Group.
    Omura GA; Hubbard JL; Hatch KD; Schlaerth JB; Blessing JA
    Am J Clin Oncol; 1992 Jun; 15(3):185-7. PubMed ID: 1590269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.